Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy.
about
Monocytes as regulators of inflammation and HIV-related comorbidities during cARTAlarmins and central nervous system inflammation in HIV-associated neurological disorders.HIV-associated neurocognitive disorder.HIV DNA in CD14+ reservoirs is associated with regional brain atrophy in patients naive to combination antiretroviral therapy.CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders.Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-aHIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients.JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.Factors related to HIV-associated neurocognitive impairment differ with age.Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disordersRole of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais.Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone.Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children.Presence of high-risk human papillomavirus genotype and human immunodeficiency virus DNA in anal high-grade and low-grade squamous intraepithelial lesions.Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infectionNeurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.Nanomedicines for the Treatment of CNS Diseases.Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder.Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection.HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents.Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study.EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment.In Vitro Blood-Brain Barrier Modeling adapted for Peripheral Blood Mononuclear Cell Transmigration from HIV-Positive Patients for Clinical Research on Therapeutic Drug Intervention
P2860
Q27006827-E62C8AAC-F9B1-437B-9F78-E1F93B2E7DC3Q30241037-05DAF23F-6458-421C-A99A-0FE3B1F685A2Q33939729-2620E325-6288-42A5-A07F-40B6BBBFB27EQ34221268-3D4FD9AE-0C17-4D51-A4E5-F60EE3262045Q34376412-DCDE3015-EA26-4215-93D8-AAD226518AD7Q34718135-4C9CE2FF-A1E6-4D1C-A225-4CF4CDD71CB4Q34922069-FB2E21EE-60F0-43E0-8969-3AAED7E618CBQ35005863-258EE28A-44E2-422A-9629-25CD1B101C2FQ35058626-5D62BA71-1B42-4F66-B002-0BD9EAD8A93FQ35154529-CE8BBC60-FE36-480E-9DCE-36C31A231246Q35652578-38DBDC96-7288-45E7-8262-084E2BBBA5C7Q36250020-0EDEA62B-2BA6-4CBE-940F-27C3285206B5Q36281845-14EE6F0B-7B59-4E89-9702-4C8B9CB8C0D9Q36509571-B9018FAC-9900-4B55-9FBD-5ABF72034A98Q36509615-3B0E84B0-5496-4AB1-8FC8-E1555781D349Q37351669-9E19B7A4-2E32-4A99-A370-C34B33F60386Q38887687-4E10C7EF-00AE-496D-B2D3-6E04DEFB39C1Q39114740-2B9541A2-DAFA-4EB0-901C-5066FFF71F21Q39331854-8237652F-3A89-4CDB-B4F4-DF4BA17C39ECQ40314419-2A8B3049-B44E-40D9-8D5A-2220D04447CAQ40322637-E9E3A909-A5C8-4E42-B66D-5CEDF622A974Q40478740-C1201BEF-1C9E-4115-8FED-1130854DD030Q42160092-9E702604-ADCB-4965-B55F-09017F3EED89Q42255469-F1D36167-D93B-4A28-A4E9-041C961F7064Q55255033-8B8D172A-49E8-411D-A246-371BD70909F6Q58775726-5FCC0CC9-A03D-4997-92F5-6A6FFFE1A458
P2860
Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@en
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@nl
type
label
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@en
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@nl
prefLabel
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@en
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@nl
P2093
P2860
P1476
Failure to clear intra-monocyt ...... mbined antiretroviral therapy.
@en
P2093
B Shiramizu
D Troelstrup
J Ananworanich
P Praihirunkit
P Sithinamsuwan
S Rattanamanee
SEARCH 001.1 Study Group
T Chalermchai
U Siangphoe
P2860
P2888
P356
10.1007/S13365-011-0068-8
P577
2011-12-30T00:00:00Z